IFNG and non-small cell lung carcinoma: The findings of this phase II trial showed that (i) IFN-γ-Dex is a very well tolerated immunotherapy, (ii) effective clinical-grade IFN-γ-Dex production is feasible, and (iii) IFN-γ-Dex boosts NKp30-dependent NK cell functions while having no detectable induction of antigen-specific T cell responses when used as maintenance immunotherapy in chemotherapy-stabilized/responding NSCLC patients [95].